Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Typhoid-Paratyphoid Vaccines"" wg kryterium: Temat


Tytuł :
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Autorzy :
Shakya M; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal. Electronic address: .
Voysey M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Theiss-Nyland K; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Colin-Jones R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Pant D; Patan Academy of Health Sciences, Patan Hospital, Lalitpur, Nepal.
Adhikari A; Nepal Family Development Foundation, Lalitpur, Nepal.
Tonks S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Mujadidi YF; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
O'Reilly P; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Mazur O; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Kelly S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Liu X; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Maharjan A; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal.
Dahal A; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal.
Haque N; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal.
Pradhan A; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal.
Shrestha S; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal.
Joshi M; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal.
Smith N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Hill J; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Clarke J; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Stockdale L; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Jones E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Lubinda T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Bajracharya B; Wasa Pasa Polyclinics Private, Lalitpur, Nepal.
Dongol S; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal.
Karkey A; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal.
Baker S; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, UK.
Dougan G; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, UK.
Pitzer VE; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.
Neuzil KM; School of Medicine, University of Maryland, Baltimore, MD, USA.
Shrestha S; Patan Academy of Health Sciences, Patan Hospital, Lalitpur, Nepal.
Basnyat B; Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Lalitpur, Nepal; Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Pokaż więcej
Corporate Authors :
TyVAC Nepal Team
Źródło :
The Lancet. Global health [Lancet Glob Health] 2021 Nov; Vol. 9 (11), pp. e1561-e1568.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Typhoid Fever/*prevention & control
Typhoid-Paratyphoid Vaccines/*immunology
Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Nepal/epidemiology ; Typhoid Fever/epidemiology ; Typhoid-Paratyphoid Vaccines/administration & dosage ; Vaccines, Conjugate/administration & dosage ; Vaccines, Conjugate/immunology
Czasopismo naukowe
Tytuł :
Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
Autorzy :
Vadrevu KM; Bharat Biotech International Limited, Genome Valley, Shameerpet, Hyderabad, India.
Raju D; Bharat Biotech International Limited, Genome Valley, Shameerpet, Hyderabad, India.
Rani S; Bharat Biotech International Limited, Genome Valley, Shameerpet, Hyderabad, India.
Reddy S; Bharat Biotech International Limited, Genome Valley, Shameerpet, Hyderabad, India.
Sarangi V; Bharat Biotech International Limited, Genome Valley, Shameerpet, Hyderabad, India.
Ella R; Bharat Biotech International Limited, Genome Valley, Shameerpet, Hyderabad, India. Electronic address: .
Javvaji B; Sri Srinivasa Children's Hospital, Vijayawada, India.
Mahantshetty NS; Priya Children's Hospital, Vijayawada, India.
Battu S; KLE Hospital, Belgavi, India.
Levine MM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA.
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Oct 29; Vol. 39 (45), pp. 6682-6690. Date of Electronic Publication: 2021 Oct 05.
Typ publikacji :
Journal Article
MeSH Terms :
Typhoid Fever*
Typhoid-Paratyphoid Vaccines*
Antibodies, Bacterial ; Antibody Formation ; Child ; Child, Preschool ; Humans ; Immunization, Secondary ; Polysaccharides ; Salmonella typhi ; Tetanus Toxoid ; Vaccination ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study.
Autorzy :
Batool R; Department of Pediatrics and Child Health, Aga Khan University Hospital, National Stadium Rd, Aga Khan University Hospital, Karachi City, Sindh 74800, Pakistan; Adolescent, and Maternal Health, Faculty of Medicine and Health Technology, Tampere University, Kalevantie 4, 33100 Tampere, Finland. Electronic address: .
Tahir Yousafzai M; Department of Pediatrics and Child Health, Aga Khan University Hospital, National Stadium Rd, Aga Khan University Hospital, Karachi City, Sindh 74800, Pakistan; Kirby Institute, University of New South Wales, Level 6, Wallace Wurth Building, High Street, Kensington, NSW 2052, Australia. Electronic address: .
Qureshi S; Department of Pediatrics and Child Health, Aga Khan University Hospital, National Stadium Rd, Aga Khan University Hospital, Karachi City, Sindh 74800, Pakistan. Electronic address: .
Ali M; Department of Pediatrics and Child Health, Aga Khan University Hospital, National Stadium Rd, Aga Khan University Hospital, Karachi City, Sindh 74800, Pakistan. Electronic address: .
Sadaf T; Department of Pediatrics and Child Health, Aga Khan University Hospital, National Stadium Rd, Aga Khan University Hospital, Karachi City, Sindh 74800, Pakistan. Electronic address: .
Mehmood J; Department of Pediatrics and Child Health, Aga Khan University Hospital, National Stadium Rd, Aga Khan University Hospital, Karachi City, Sindh 74800, Pakistan. Electronic address: .
Ashorn P; Adolescent, and Maternal Health, Faculty of Medicine and Health Technology, Tampere University, Kalevantie 4, 33100 Tampere, Finland; Department of Paediatrics, Tampere University Hospital, Kalevantie 4, 33100 Tampere, Finland. Electronic address: .
Naz Qamar F; Department of Pediatrics and Child Health, Aga Khan University Hospital, National Stadium Rd, Aga Khan University Hospital, Karachi City, Sindh 74800, Pakistan. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Sep 24; Vol. 39 (40), pp. 5858-5865. Date of Electronic Publication: 2021 Aug 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Typhoid Fever*/epidemiology
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Case-Control Studies ; Child ; Humans ; Pakistan/epidemiology ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
Autorzy :
Patel PD; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Patel P; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Liang Y; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Meiring JE; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Misiri T; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Mwakiseghile F; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Tracy JK; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Masesa C; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Msuku H; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Banda D; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Mbewe M; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Henrion M; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Adetunji F; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Simiyu K; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Rotrosen E; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Birkhold M; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Nampota N; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Nyirenda OM; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Kotloff K; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Gmeiner M; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Dube Q; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Kawalazira G; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Laurens MB; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Heyderman RS; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Gordon MA; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Neuzil KM; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Pokaż więcej
Corporate Authors :
TyVAC Malawi Team
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 16; Vol. 385 (12), pp. 1104-1115.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Polysaccharides, Bacterial*/adverse effects
Typhoid-Paratyphoid Vaccines*/adverse effects
Typhoid Fever/*prevention & control
Child ; Child, Preschool ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Incidence ; Infant ; Intention to Treat Analysis ; Malawi ; Male ; Meningococcal Vaccines/adverse effects ; Salmonella typhi ; Typhoid Fever/epidemiology ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
Gagandeep Kang: helping to shape a healthier India.
Autorzy :
Lane R
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2021 Sep 11; Vol. 398 (10304), pp. 947.
Typ publikacji :
Biography; Historical Article; Journal Article
MeSH Terms :
Rotavirus Vaccines*
Typhoid-Paratyphoid Vaccines*
Rotavirus Infections/*prevention & control
COVID-19/prevention & control ; COVID-19 Vaccines ; Health Care Reform ; History, 20th Century ; History, 21st Century ; Humans ; India ; Typhoid Fever/prevention & control
Personal Name as Subject :
Kang G
Czasopismo naukowe
Tytuł :
S. Typhi derived vaccines and a proposal for outer membrane vesicles (OMVs) as potential vaccine for typhoid fever.
Autorzy :
Haque S; Feinstein Institute for Medical Research, Northwell Health, 350 Community Drive, Manhasset, NY, 11030, USA. Electronic address: .
Swami P; Feinstein Institute for Medical Research, Northwell Health, 350 Community Drive, Manhasset, NY, 11030, USA. Electronic address: .
Khan A; Faculty of Applied Sciences and Biotechnology, Shoolini University, Solan, Himachal, Pradesh, India. Electronic address: .
Pokaż więcej
Źródło :
Microbial pathogenesis [Microb Pathog] 2021 Sep; Vol. 158, pp. 105082. Date of Electronic Publication: 2021 Jul 13.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Vaccines*
Humans ; O Antigens ; Polysaccharides, Bacterial ; Salmonella typhi
Czasopismo naukowe
Tytuł :
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.
Autorzy :
Sirima SB; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Ouedraogo A; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Barry N; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Siribie M; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Tiono A; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Nébié I; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Konaté A; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Berges GD; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Diarra A; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Ouedraogo M; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Bougouma EC; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Soulama I; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Hema A; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.
Datta S; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Liang Y; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Rotrosen ET; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Tracy JK; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Jamka LP; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Oshinsky JJ; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Pasetti MF; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Laurens MB; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: .
Pokaż więcej
Źródło :
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2021 Jul; Vol. 108, pp. 465-472. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :
Polysaccharides, Bacterial/*adverse effects
Typhoid-Paratyphoid Vaccines/*adverse effects
Burkina Faso ; Double-Blind Method ; Female ; Humans ; Infant ; Male ; Measles Vaccine/administration & dosage ; Polysaccharides, Bacterial/administration & dosage ; Polysaccharides, Bacterial/immunology ; Rubella Vaccine/administration & dosage ; Typhoid-Paratyphoid Vaccines/administration & dosage ; Typhoid-Paratyphoid Vaccines/immunology ; Vaccines, Conjugate/adverse effects ; Vaccines, Conjugate/immunology ; Yellow Fever Vaccine/administration & dosage
Czasopismo naukowe
Tytuł :
Immunity and Protection Provided by Live Modified Vaccines Against Paratyphoid Salmonella in Poultry-An Applied Perspective.
Autorzy :
Hofacre CL; Southern Poultry Research Group, Inc., Watkinsville, GA 30677, .
Rosales AG; Integrated Poultry Health Services, Inc., Watkinsville, GA 30677.
Costa MD; Zoetis Inc., Durham, NC 27703.
Cookson K; Zoetis Inc., Durham, NC 27703.
Schaeffer J; Zoetis Inc., Durham, NC 27703.
Jones MK; Southern Poultry Research Group, Inc., Watkinsville, GA 30677.
Pokaż więcej
Źródło :
Avian diseases [Avian Dis] 2021 Jun; Vol. 65 (2), pp. 295-302.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Typhoid-Paratyphoid Vaccines*/immunology
Typhoid-Paratyphoid Vaccines*/standards
Paratyphoid Fever/*veterinary
Poultry Diseases/*prevention & control
Salmonella enterica/*immunology
Animals ; Chickens ; Humans ; Immunization, Secondary/veterinary ; Paratyphoid Fever/immunology ; Paratyphoid Fever/prevention & control ; Poultry ; Poultry Diseases/immunology ; Poultry Diseases/microbiology ; Turkeys ; Vaccines, Attenuated/genetics ; Vaccines, Inactivated/genetics
Czasopismo naukowe
Tytuł :
Salmonella Typhi Vi polysaccharide conjugate vaccine protects infants and children against typhoid fever.
Autorzy :
Crump JA; Centre for International Health, University of Otago, Dunedin, New Zealand. Electronic address: .
Oo WT; Department of Microbiology, University of Medicine 1, Yangon, Myanmar.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2021 Aug 21; Vol. 398 (10301), pp. 643-644. Date of Electronic Publication: 2021 Aug 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Child ; Humans ; Infant ; Polysaccharides ; Salmonella typhi/immunology ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
Evaluation of Vaccine Safety After the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.
Autorzy :
Longley AT; National Foundation for the Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Date K; Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Luby SP; Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California,USA.
Bhatnagar P; World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Bentsi-Enchill AD; Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Goyal V; World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Shimpi R; World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Katkar A; World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Yewale V; Dr Yewale Multi Specialty Hospital for Children, Navi Mumbai, India.
Jayaprasad N; World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Horng L; Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California,USA.
Kunwar A; World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Harvey P; World Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Haldar P; Ministry of Health and Family Welfare, Government of India, New Delhi, India.
Dutta S; National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, India.
Gidudu JF; Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Pokaż więcej
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Aug 16; Vol. 73 (4), pp. e927-e933.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Typhoid Fever*/epidemiology
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*/adverse effects
Adverse Drug Reaction Reporting Systems ; Child ; Humans ; India/epidemiology ; Public Sector ; Vaccination ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
Use of the typhoid conjugate vaccine in endemic settings.
Autorzy :
Khanam F; International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Qadri F; International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Global health [Lancet Glob Health] 2021 Aug; Vol. 9 (8), pp. e1047-e1048.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Typhoid Fever*/epidemiology
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Humans ; Vaccination ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
Cost effectiveness of typhoid vaccination in India.
Autorzy :
Chauhan AS; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Kapoor I; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Rana SK; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Kumar D; The Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Vellore 632 004, India.
Gupta M; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
John J; Department of Community Health, Christian Medical College, Vellore 632 002, India.
Kang G; The Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Vellore 632 004, India.
Prinja S; Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Jul 05; Vol. 39 (30), pp. 4089-4098. Date of Electronic Publication: 2021 Jun 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Typhoid Fever*/epidemiology
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Child ; Cost-Benefit Analysis ; Humans ; Immunization Programs ; India/epidemiology ; Vaccination ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
Introduction of typhoid vaccine in the expanded immunization program of Pakistan.
Autorzy :
Aslam F; Business Administration, Shenyang Pharmaceutical University, Shenyang, China.
Yue Y; Business Administration, Shenyang Pharmaceutical University, Shenyang, China.
Aziz M; Department of Pharmacy Administration and Clinical Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Pokaż więcej
Źródło :
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Jul 03; Vol. 17 (7), pp. 2132. Date of Electronic Publication: 2021 Jan 31.
Typ publikacji :
Journal Article
MeSH Terms :
Typhoid Fever*/epidemiology
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Child ; Humans ; Immunization Programs ; India ; Pakistan/epidemiology ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults.
Autorzy :
Choi SK; R&D Center, EuBiologics Co., Ltd., Chuncheon, Republic of Korea; Department of Biotechnology, Korea University, Seoul, Republic of Korea.
Baik YO; R&D Center, EuBiologics Co., Ltd., Chuncheon, Republic of Korea.
Kim CW; Department of Biotechnology, Korea University, Seoul, Republic of Korea.
Kim SK; R&D Center, EuBiologics Co., Ltd., Chuncheon, Republic of Korea.
Oh IN; R&D Center, EuBiologics Co., Ltd., Chuncheon, Republic of Korea.
Yoon H; R&D Center, EuBiologics Co., Ltd., Chuncheon, Republic of Korea.
Yu D; R&D Center, EuBiologics Co., Ltd., Chuncheon, Republic of Korea.
Lee C; R&D Center, EuBiologics Co., Ltd., Chuncheon, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 May 06; Vol. 39 (19), pp. 2620-2627. Date of Electronic Publication: 2021 Apr 10.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms :
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*/adverse effects
Adolescent ; Adult ; Antibodies, Bacterial ; Bacterial Proteins ; Child ; Child, Preschool ; Humans ; Immunogenicity, Vaccine ; Middle Aged ; Vaccines, Conjugate/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł :
Typhoid and paratyphoid fever: a clinical seminar.
Autorzy :
Manesh A; Department of Infectious Diseases, Christian Medical College, Vellore, India.
Meltzer E; Department of Medicine `C', Center for Geographic Medicine, Sheba Medical Center, Tel-Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Jin C; Oxford Vaccine Group, Department of Pediatrics, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Britto C; Oxford Vaccine Group, Department of Pediatrics, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Deodhar D; Department of Infectious Diseases, Christian Medical College, Vellore, India.
Radha S; Department of Infectious Diseases, Christian Medical College, Vellore, India.
Schwartz E; Department of Medicine `C', Center for Geographic Medicine, Sheba Medical Center, Tel-Hashomer, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rupali P; Department of Infectious Diseases, Christian Medical College, Vellore, India.
Pokaż więcej
Źródło :
Journal of travel medicine [J Travel Med] 2021 Apr 14; Vol. 28 (3).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Paratyphoid Fever*/diagnosis
Paratyphoid Fever*/drug therapy
Paratyphoid Fever*/epidemiology
Paratyphoid Fever*/prevention & control
Travel-Related Illness*
Typhoid Fever*/diagnosis
Typhoid Fever*/drug therapy
Typhoid Fever*/epidemiology
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Africa ; Humans ; Pakistan ; Salmonella paratyphi A/physiology ; Salmonella typhi
Czasopismo naukowe
Tytuł :
Richard Pfeiffer's typhoid vaccine and Almroth Wright's claim to priority.
Autorzy :
Williamson JD; Alexander Fleming Laboratory Museum, United Kingdom.
Gould KG; Department of Infectious Diseases, Faculty of Medicine, St Mary's Campus, Imperial College London, Paddington, London W2 1PG, United Kingdom.
Brown K; Trust Archivist and Curator, Alexander Fleming Laboratory Museum, Imperial College Healthcare NHS Trust, St Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Apr 08; Vol. 39 (15), pp. 2074-2079. Date of Electronic Publication: 2021 Mar 13.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cholera*/prevention & control
Military Personnel*
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Animals ; Berlin ; Humans ; Male ; Vaccination
Czasopismo naukowe
Tytuł :
Adverse Events Following Immunization With Combined vs Concurrent Monovalent Hepatitis A and Typhoid Vaccines in Children.
Autorzy :
Furuya-Kanamori L; Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australia.
Dutton P; Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australia.
Leeb A; Illawarra Medical Centre, Perth, Australia.
Mills DJ; Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australia.; Travel Medicine Alliance Clinics, Brisbane, Australia.
Andrews R; Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australia.
Lau CL; Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, Australia.; Travel Medicine Alliance Clinics, Brisbane, Australia.
Pokaż więcej
Źródło :
Journal of the Pediatric Infectious Diseases Society [J Pediatric Infect Dis Soc] 2021 Mar 26; Vol. 10 (2), pp. 192-195.
Typ publikacji :
Journal Article
MeSH Terms :
Hepatitis A*/prevention & control
Typhoid-Paratyphoid Vaccines*/adverse effects
Adolescent ; Child ; Hepatitis A Vaccines/adverse effects ; Humans ; Vaccination ; Vaccines, Combined/adverse effects
Czasopismo naukowe
Tytuł :
Strategies for typhoid conjugate vaccines in endemic nations.
Autorzy :
Kalule JB; College of Veterinary Medicine, Animal Resources, and Biosecurity, Makerere University, Kampala, Uganda. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Infectious diseases [Lancet Infect Dis] 2021 Mar; Vol. 21 (3), pp. 320-321.
Typ publikacji :
Letter; Comment
MeSH Terms :
Typhoid Fever*/epidemiology
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Cost-Benefit Analysis ; Humans ; Salmonella typhi/immunology ; Vaccines, Conjugate
Opinia redakcyjna
Tytuł :
Strategies for typhoid conjugate vaccines in endemic nations - Authors' reply.
Autorzy :
Pitzer VE; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.
Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Bilcke J; Center for Health Economic Research and Modelling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, 2610 Antwerp, Belgium. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Infectious diseases [Lancet Infect Dis] 2021 Mar; Vol. 21 (3), pp. 321-322.
Typ publikacji :
Letter; Comment
MeSH Terms :
Typhoid Fever*/epidemiology
Typhoid Fever*/prevention & control
Typhoid-Paratyphoid Vaccines*
Cost-Benefit Analysis ; Humans ; Salmonella typhi/immunology ; Vaccines, Conjugate
Opinia redakcyjna
Tytuł :
Syntheses of Salmonella Paratyphi A Associated Oligosaccharide Antigens and Development towards Anti-Paratyphoid Fever Vaccines.
Autorzy :
Dhara D; Division of Molecular Medicine, Bose Institute, P-1/12, C.I.T. Scheme VII M, Kolkata, 700054, India.; Current address: Unité de Chimie des Biomolécules, Institut Pasteur, 25/28 Rue du Docteur Roux, Paris Cedex 15, 75724, France.
Baliban SM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201-1509, USA.
Huo CX; Department of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.; Institute for Quantitative Health Science & Engineering, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.
Rashidijahanabad Z; Department of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.; Institute for Quantitative Health Science & Engineering, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.
Sears KT; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201-1509, USA.
Nick ST; Department of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.; Institute for Quantitative Health Science & Engineering, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.
Misra AK; Division of Molecular Medicine, Bose Institute, P-1/12, C.I.T. Scheme VII M, Kolkata, 700054, India.
Tennant SM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201-1509, USA.
Huang X; Department of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.; Institute for Quantitative Health Science & Engineering, Michigan State University, 578 South Shaw Lane, East Lansing, MI, 48824, USA.; Department of Biomedical Engineering, Michigan State University, East Lansing, MI, 48824, USA.
Pokaż więcej
Źródło :
Chemistry (Weinheim an der Bergstrasse, Germany) [Chemistry] 2020 Dec 04; Vol. 26 (68), pp. 15953-15968. Date of Electronic Publication: 2020 Oct 22.
Typ publikacji :
Journal Article
MeSH Terms :
Oligosaccharides*/immunology
Paratyphoid Fever*/prevention & control
Salmonella paratyphi A*/immunology
Typhoid-Paratyphoid Vaccines*/administration & dosage
Typhoid-Paratyphoid Vaccines*/chemistry
Animals ; Antibodies, Bacterial/immunology ; Antigens, Bacterial/immunology ; Mice ; Vaccines, Synthetic
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies